Edition:
United States

Profile: Celgene Corp (CELG.O)

CELG.O on Nasdaq

143.89USD
22 Sep 2017
Change (% chg)

$0.11 (+0.08%)
Prev Close
$143.78
Open
$143.31
Day's High
$144.19
Day's Low
$141.75
Volume
3,549,466
Avg. Vol
3,783,014
52-wk High
$144.59
52-wk Low
$96.93

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Company Address

Celgene Corp

86 Morris Ave
SUMMIT   NJ   07901-3915
P: +1908.6739000
F: +1302.6555049

Company Web Links